#BEGIN_DRUGCARD DB01321

# AHFS_Codes:
Not Available

# ATC_Codes:
J01FA07

# Absorption:
Not Available

# Biotransformation:
Not Available

# Brand_Mixtures:
Not Available

# Brand_Names:
Josacine
Kitasamycin A3
Turimycin A5

# CAS_Registry_Number:
16846-24-5

# ChEBI_ID:
Not Available

# Chemical_Formula:
C42H69NO15

# Chemical_IUPAC_Name:
(2S,3S,4R,6S)-6-{[(2R,3S,4R,5R,6S)-6-{[(4R,5S,6S,7R,9R,10R,11E,13E,16R)-4-(acetyloxy)-10-hydroxy-5-methoxy-9,16-dimethyl-2-oxo-7-(2-oxoethyl)-1-oxacyclohexadeca-11,13-dien-6-yl]oxy}-4-(dimethylamino)-5-hydroxy-2-methyloxan-3-yl]oxy}-4-hydroxy-2,4-dimethyloxan-3-yl 3-methylbutanoate

# Chemical_Structure:
Not Available

# Creation_Date:
2007-06-30 11:19:12 -0600

# DPD_Drug_ID_Number:
Not Available

# Description:
A macrolide antibiotic from Streptomyces narbonensis. The drug has antimicrobial activity against a wide spectrum of pathogens. [PubChem]

# Dosage_Forms:
Not Available

# Drug_Category:
Anti-Bacterial Agents
Antibacterial Agents
Macrolides

# Drug_Interactions:
Alprazolam	The macrolide, josamycin, may increase the effect of the benzodiazepine, alprazolam.
Aminophylline	The macrolide, josamycin, may increase the effect and toxicity of the theophylline derivative, aminophylline.
Astemizole	Increased risk of cardiotoxicity and arrhythmias
Atorvastatin	The macrolide, josamycin, may increase the toxicity of the statin, atorvastatin.
Bromocriptine	Erythromycin increases serum levels of bromocriptine
Buspirone	The macrolide, josamycin, may increase the effect and toxicity of buspirone.
Carbamazepine	The macrolide, josamycin, may increase the effect of carbamazepine.
Cerivastatin	The macrolide, josamycin, may increase the toxicity of the statin, cerivastatin.
Cilostazol	Erythromycin increases the effect of cilostazol
Cisapride	Increased risk of cardiotoxicity and arrhythmias
Citalopram	Possible serotoninergic sydrome with this combination
Clozapine	Erythromycin increases the effect of clozapine
Cyclosporine	The macrolide, josamycin, may increase the effect of cyclosporine.
Diazepam	The macrolide, josamycin, may increase the effect of the benzodiazepine, diazepam.
Digoxin	The macrolide, josamycin, may increase the effect of digoxin in 10% of patients.
Dihydroergotamine	Possible ergotism and severe ischemia with this combination
Docetaxel	Josamycin may increase the serum levels and toxicity of docetaxel.
Ergotamine	Possible ergotism and severe ischemia with this combination
Felodipine	Erythromycin increases the effect of felodipine
Fluoxetine	Possible serotoninergic syndrome with this combination
Grepafloxacin	Increased risk of cardiotoxicity and arrhythmias
Imatinib	The macrolide, josamycin, may increase the serum concentration of imatinib.
Itraconazole	The macrolide, josamycin, may increase the effect and toxicity of itraconazole.
Levofloxacin	Increased risk of cardiotoxicity and arrhythmias
Lovastatin	The macrolide, josamycin, may increase the toxicity of the statin, lovastatin.
Mesoridazine	Increased risk of cardiotoxicity and arrhythmias
Methysergide	Possible ergotism and severe ischemia with this combination
Midazolam	The macrolide, josamycin, may increase the effect of the benzodiazepine, midazolam.
Moxifloxacin	Increased risk of cardiotoxicity and arrhythmias
Oxtriphylline	The macrolide, josamycin, may increase the effect and toxicity of the theophylline derivative, oxtriphylline.
Pimozide	Increased risk of cardiotoxicity and arrhythmias
Repaglinide	The macrolide, josamycin, may increase the effect of repaglinide.
Rifabutin	The rifamycin, rifabutin, may decrease the effect of the macrolide, josamycin.
Rifampin	The rifamycin, rifampin, may decrease the effect of the macrolide, josamycin.
Terfenadine	Increased risk of cardiotoxicity and arrhythmias
Theophylline	The macrolide, josamycin, may increase the effect and toxicity of theophylline.
Thioridazine	Increased risk of cardiotoxicity and arrhythmias
Triazolam	The macrolide, josamycin, may increase the effect of the benzodiazepine, triazolam.

# Drug_Reference:
20186698	Przybylski P, Pyta K, Stefanska J, Brzezinski B, Bartl F: Structure elucidation, complete NMR assignment and PM5 theoretical studies of new hydroxy-aminoalkyl-alpha,beta-unsaturated derivatives of the macrolide antibiotic josamycin. Magn Reson Chem. 2010 Apr;48(4):286-96.

# Drug_Type:
Approved
Small Molecule

# Experimental_Caco2_Permeability:
Not Available

# Experimental_LogP_Hydrophobicity:
Not Available

# Experimental_Logs:
Not Available

# Experimental_Water_Solubility:
Not Available

# Food_Interactions:
Not Available

# GenBank_ID:
Not Available

# Generic_Name:
Josamycin

# HET_ID:
Not Available

# Half_Life:
Not Available

# InChI_Identifier:
InChI=1S/C42H69NO15/c1-23(2)19-32(47)56-40-27(6)53-34(22-42(40,8)50)57-37-26(5)54-41(36(49)35(37)43(9)10)58-38-29(17-18-44)20-24(3)30(46)16-14-12-13-15-25(4)52-33(48)21-31(39(38)51-11)55-28(7)45/h12-14,16,18,23-27,29-31,34-41,46,49-50H,15,17,19-22H2,1-11H3/b13-12+,16-14+/t24-,25-,26-,27+,29+,30+,31-,34+,35-,36-,37-,38+,39+,40+,41+,42-/m1/s1

# InChI_Key:
InChIKey=XJSFLOJWULLJQS-NGVXBBESSA-N

# Indication:
For the treatment of bacterial infections.

# KEGG_Compound_ID:
C12662

# KEGG_Drug_ID:
D01235

# LIMS_Drug_ID:
1321

# Mechanism_Of_Action:
The mechanism of action of macrolides such as Josamycin is via inhibition of bacterial protein biosynthesis by binding reversibly to the subunit 50S of the bacterial ribosome, thereby inhibiting translocation of peptidyl tRNA. This action is mainly bacteriostatic, but can also be bactericidal in high concentrations. Macrolides tend to accumulate within leukocytes, and are therefore actually transported into the site of infection.

# Melting_Point:
131.5 Â°C

# Molecular_Weight_Avg:
827.995

# Molecular_Weight_Mono:
827.466720543

# Organisms_Affected:
Enteric bacteria and other eubacteria

# PDB_Experimental_ID:
Not Available

# PDB_Homology_ID:
Not Available

# PDRhealth_Link:
Not Available

# Pathways:
Not Available

# PharmGKB_ID:
PA164749133

# Pharmacology:
Josamycin is a macrolide antibiotic from <i>Streptomyces narbonensis</i>. The drug has antimicrobial activity against a wide spectrum of pathogens.

# Predicted_LogP_Hydrophobicity:
3.47

# Predicted_LogS:
-4.2

# Predicted_Water_Solubility:
5.35e-02 g/l

# Primary_Accession_No:
DB01321

# Protein_Binding:
Not Available

# PubChem_Compound_ID:
5282165

# PubChem_Substance_ID:
46505431

# RxList_Link:
Not Available

# Salts:
Not Available

# Secondary_Accession_No:
Not Available

# Smiles_String_canonical:
Not Available

# Smiles_String_isomeric:
CO[C@H]1[C@H](OC(=O)C)CC(=O)O[C@H](C)C\C=C\C=C\[C@H](O)[C@H](C)C[C@H](CC=O)[C@@H]1O[C@@H]1O[C@H](C)[C@@H](O[C@@H]2O[C@@H](C)[C@H](OC(=O)CC(C)C)[C@](C)(O)C2)[C@H](N(C)C)[C@H]1O

# State:
solid

# Structure:
1

# SwissProt_ID:
Not Available

# SwissProt_Name:
Not Available

# Synonyms:
Antibiotic yl-704 A3
JM
Josamicina [inn-spanish]
Josamycine [inn-french]
Josamycinum [inn-latin]
Leucomycin A3
Leucomycin V, 3-acetate 4(sup B)-(3-methylbutanoate)
Leucomycin V, 3-acetate 4(sup beta)-(3-methylbutanoate)
Leucomycin V, 3-acetate 4B-(3-methylbutanoate)

# Synthesis_Reference:
Not Available

# Toxicity:
Not Available

# Update_Date:
2013-02-08 16:20:04 -0700

# Wikipedia_Link:
http://en.wikipedia.org/wiki/Josamycin

# pKa_Isoelectric_Point:
Not Available

# Phase_1_Metabolizing_Enzyme_1_Gene_Name:
CYP3A4

# Phase_1_Metabolizing_Enzyme_1_ID:
4512

# Phase_1_Metabolizing_Enzyme_1_Name:
Cytochrome P450 3A4

# Phase_1_Metabolizing_Enzyme_1_Protein_Sequence:
>Cytochrome P450 3A4
MALIPDLAMETWLLLAVSLVLLYLYGTHSHGLFKKLGIPGPTPLPFLGNILSYHKGFCMF
DMECHKKYGKVWGFYDGQQPVLAITDPDMIKTVLVKECYSVFTNRRPFGPVGFMKSAISI
AEDEEWKRLRSLLSPTFTSGKLKEMVPIIAQYGDVLVRNLRREAETGKPVTLKDVFGAYS
MDVITSTSFGVNIDSLNNPQDPFVENTKKLLRFDFLDPFFLSITVFPFLIPILEVLNICV
FPREVTNFLRKSVKRMKESRLEDTQKHRVDFLQLMIDSQNSKETESHKALSDLELVAQSI
IFIFAGYETTSSVLSFIMYELATHPDVQQKLQEEIDAVLPNKAPPTYDTVLQMEYLDMVV
NETLRLFPIAMRLERVCKKDVEINGMFIPKGVVVMIPSYALHRDPKYWTEPEKFLPERFS
KKNKDNIDPYIYTPFGSGPRNCIGMRFALMNMKLALIRVLQNFSFKPCKETQIPLKLSLG
GLLQPEKPVVLKVESRDGTVSGA

# Phase_1_Metabolizing_Enzyme_1_SwissProt_ID:
P08684

# Drug_Target_1_Cellular_Location:
Not Available

# Drug_Target_1_Chromosome_Location:
Not Available

# Drug_Target_1_Drug_References:
10898684	Tait-Kamradt A, Davies T, Cronan M, Jacobs MR, Appelbaum PC, Sutcliffe J: Mutations in 23S rRNA and ribosomal protein L4 account for resistance in pneumococcal strains selected in vitro by macrolide passage. Antimicrob Agents Chemother. 2000 Aug;44(8):2118-25.

# Drug_Target_1_Essentiality:
Essential

# Drug_Target_1_GenAtlas_ID:
Not Available

# Drug_Target_1_GenBank_ID_Gene:
L42023

# Drug_Target_1_GenBank_ID_Protein:
3212176

# Drug_Target_1_GeneCard_ID:
rplD

# Drug_Target_1_Gene_Name:
rplD

# Drug_Target_1_Gene_Sequence:
>1020 bp
ATGGCAATTAAAATTGGTATCAATGGTTTTGGTCGTATCGGCCGTATCGTATTCCGTGCA
GCACAACACCGTGATGACATTGAAGTTGTAGGTATTAACGACTTAATCGACGTTGAATAC
ATGGCTTATATGTTGAAATATGATTCAACTCACGGTCGTTTCGACGGCACTGTTGAAGTG
AAAGATGGTAACTTAGTGGTTAATGGTAAAACTATCCGTGTAACTGCAGAACGTGATCCA
GCAAACTTAAACTGGGGTGCAATCGGTGTTGATATCGCTGTTGAAGCGACTGGTTTATTC
TTAACTGATGAAACTGCTCGTAAACATATCACTGCAGGCGCAAAAAAAGTTGTATTAACT
GGCCCATCTAAAGATGCAACCCCTATGTTCGTTCGTGGTGTAAACTTCAACGCATACGCA
GGTCAAGATATCGTTTCTAACGCATCTTGTACAACAAACTGTTTAGCTCCTTTAGCACGT
GTTGTTCATGAAACTTTCGGTATCAAAGATGGTTTAATGACCACTGTTCACGCAACGACT
GCAACTCAAAAAACTGTGGATGGTCCATCAGCTAAAGACTGGCGCGGCGGCCGCGGTGCA
TCACAAAACATCATTCCATCTTCAACAGGTGCAGCGAAAGCAGTAGGTAAAGTATTACCT
GCATTAAACGGTAAATTAACTGGTATGGCTTTCCGTGTTCCAACGCCAAACGTATCTGTT
GTTGATTTAACAGTTAATCTTGAAAAACCAGCTTCTTATGATGCAATCAAACAAGCAATC
AAAGATGCAGCGGAAGGTAAAACGTTCAATGGCGAATTAAAAGGCGTATTAGGTTACACT
GAAGATGCTGTTGTTTCTACTGACTTCAACGGTTGTGCTTTAACTTCTGTATTTGATGCA
GACGCTGGTATCGCATTAACTGATTCTTTCGTTAAATTGGTATCTTGGTACGATAACGAA
ACGGGTTACTCAAACAAAGTATTAGACTTAGTAGCTCATATCTACAACTACAAAGGCTAA

# Drug_Target_1_General_Function:
Translation, ribosomal structure and biogenesis

# Drug_Target_1_General_References:
10498727	Allen T, Shen P, Samsel L, Liu R, Lindahl L, Zengel JM: Phylogenetic analysis of L4-mediated autogenous control of the S10 ribosomal protein operon. J Bacteriol. 1999 Oct;181(19):6124-32.
12604536	Peric M, Bozdogan B, Jacobs MR, Appelbaum PC: Effects of an efflux mechanism and ribosomal mutations on macrolide susceptibility of Haemophilus influenzae clinical isolates. Antimicrob Agents Chemother. 2003 Mar;47(3):1017-22.
7542800	Fleischmann RD, Adams MD, White O, Clayton RA, Kirkness EF, Kerlavage AR, Bult CJ, Tomb JF, Dougherty BA, Merrick JM, et al.: Whole-genome random sequencing and assembly of Haemophilus influenzae Rd. Science. 1995 Jul 28;269(5223):496-512.
8722027	Zengel JM, Vorozheikina D, Li X, Lindahl L: Regulation of the Escherichia coli S10 ribosomal protein operon by heterologous L4 ribosomal proteins. Biochem Cell Biol. 1995 Nov-Dec;73(11-12):1105-12.

# Drug_Target_1_HGNC_ID:
Not Available

# Drug_Target_1_HPRD_ID:
Not Available

# Drug_Target_1_ID:
6219

# Drug_Target_1_Locus:
Not Available

# Drug_Target_1_Molecular_Weight:
21954.2

# Drug_Target_1_Name:
50S ribosomal protein L4

# Drug_Target_1_Number_of_Residues:
200

# Drug_Target_1_PDB_ID:
Not Available

# Drug_Target_1_Pathway:
Not Available

# Drug_Target_1_Pfam_Domain_Function:
PF00573	Ribosomal_L4

# Drug_Target_1_Protein_Sequence:
>50S ribosomal protein L4
MELQVVGANALTVSETTFGREFNEALIHQVVVAYAAGARQGTRAQKTRAEVSGSGKKPWR
QKGTGRARAGDIKSPIWRSGGTTFAAKPQDHSQKVNKKMYRGAIKSILSELVRQDRLVVV
EKFELDAPKTKVLVQKLKDLAVEDALIITASLDENLFLAARNLYKVDVRDVQGIDPVSLI
AFDKVIVTVDAVKQIEEILA

# Drug_Target_1_Reaction:
Not Available

# Drug_Target_1_Signals:
None

# Drug_Target_1_Specific_Function:
Forms part of the polypeptide exit tunnel (By similarity)

# Drug_Target_1_SwissProt_ID:
P44345

# Drug_Target_1_SwissProt_Name:
RL4_HAEIN

# Drug_Target_1_Synonyms:
Not Available

# Drug_Target_1_Theoretical_pI:
10.28

# Drug_Target_1_Transmembrane_Regions:
None

#END_DRUGCARD DB01321
